Overall, this study underlines that JAK2 inhibition, using a JAK2-selective inhibitor, may lead to different effects on fibrosis, osteosclerosis, granulocytosis, erythropoiesis or platelet counts according to MPN disease stage. Here, JAK2 is linked to myeloproliferative disorder.